Descripción de la empresa
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology entity dedicated to the discovery and development of therapeutics aimed at treating fibrotic and inflammatory diseases within the United States market. The company functions within the broader healthcare sector, specifically navigating the highly specialized and capital-intensive biotechnology industry where innovation in monoclonal antibody technology drives value creation. Its current market capitalization stands at $12.10M, while its annual revenue for the trailing twelve months is not available, and the employee count is not disclosed in public filings. These valuation and operational scale figures indicate that Chemomab Therapeutics is a micro-cap entity with limited historical revenue data, suggesting it is in an early-stage development phase where cash reserves are critical for advancing its lead product candidate, Nebokitug, rather than generating immediate commercial profits.
Salud financiera
For the trailing twelve months, the company reports a net income of $-8,995,000 and an EBITDA of $-9,497,000, while annual revenue figures are not available. The significant gap between the reported net loss and the deeper EBITDA deficit reveals a substantial cost structure burdened by high operating expenses typical of clinical-stage biotechnology firms, where research and development costs are not fully offset by sales. The free cash flow stands at $-8,199,375, indicating that the company is burning cash to fund its development pipeline rather than generating liquidity from operations. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which reflects the standard accounting treatment for pre-revenue or early-revenue biotech companies where costs exceed income, resulting in negative profitability across all operational layers. The company holds $10.37M in cash against a debt position that is not available, meaning the debt-to-equity ratio is not applicable, which suggests a conservative balance sheet structure reliant on equity financing rather than leverage. The current ratio is reported at 9.08, indicating an exceptionally strong short-term liquidity position that allows the firm to cover its current liabilities many times over without immediate distress. Return on Equity is -69.5% and Return on Assets is -38.9%, metrics that reveal that management is currently deploying capital to build a future asset base rather than generating immediate returns for shareholders.
Evaluación de valoración
The company's trailing P/E ratio is not available due to its lack of earnings, while the forward P/E is listed at -56.00, implying that the market prices the stock based on future earnings expectations that are currently negative or not yet realized. The price-to-book ratio stands at 0.98, indicating that the market values the company at approximately 98% of its book value, which suggests the stock trades at a slight discount to its tangible asset base rather than a premium. The price-to-sales ratio is not available, and the EV/EBITDA is -100.69, metrics that highlight the difficulty in applying traditional valuation multiples to a firm with negative earnings and no sales history. The 52-week high is $5.88 and the 52-week low is $1.35, providing a trading range of $4.53 where the current share price must be evaluated relative to this volatility band. The beta value is 0.58, indicating that the stock's price volatility is significantly lower than the broader market, moving with less intensity than the S&P 500.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both not available, which prevents a direct comparison of earnings velocity relative to sales expansion but underscores the pre-commercial nature of the business. Since the company does not pay dividends, the dividend yield is not available and the payout ratio is 0.0%, meaning the firm retains all generated cash and any existing capital to reinvest into its research and development programs rather than distributing income to shareholders. This reinvestment strategy is standard for clinical-stage biotechs, prioritizing the advancement of their lead product candidate over immediate shareholder payouts. The overall growth and income profile is characterized by a lack of historical earnings data, a reliance on cash reserves to fund growth, and the absence of current dividend distributions, focusing entirely on the potential future value of its therapeutic pipeline.